In this study, we demonstrated that p300/CBP inhibitors predominantly inhibited the proliferation of FLT3-ITD AML cells, effectively overcame resistance to FLT3 inhibitors in both cell lines and primary AML patients, and augmented sensitivity to FLT3 inhibitors in both in vitro and in vivo models (Fig. 7). Here, EP300 is linked to acute myeloid leukemia.